Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Org 36286 · MK-8962

Recombinant protein · developed by Organon and Co

Phase 2 Most advanced trial (none active)
OGN Developer
1 Registered trials

What is Org 36286?

Org 36286, also known as corifollitropin alpha, is a single-dose subcutaneous injection studied in infertility.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MK-8962, Corifollitropin alpha
Drug type
Recombinant protein
Therapy area
Renal & urology
Developer
Organon and Co (OGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
T7K20Y2GWY

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00702585 Phase 2 Infertility Completed OGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Infertility

More from Organon and Co

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the OGN page.

Follow OGN, the company behind Org 36286

See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.